How Supply Deals At Amylyx Pharmaceuticals (AMLX) Have Changed Its Investment Story
- Amylyx Pharmaceuticals disclosed long term manufacturing and supply arrangements with Bachem Americas and a term sheet with Polypeptide Group to secure commercial scale avexitide drug substance, including minimum purchase commitments from 2028, annual supply price adjustments and a US$30 million upfront capacity reservation payment.
- The move locks in future production capacity for a potential first commercial product, while adding fixed purchase obligations and ongoing maintenance fees that could affect cash use if avexitide is delayed or not approved.
- The focus now turns to how Amylyx Pharmaceuticals’ long term avexitide supply commitments might reshape its investment narrative and risk balance.
Amylyx Pharmaceuticals Investment Narrative Recap
To own Amylyx Pharmaceuticals, you need to trust that avexitide can move from late stage development into a real product for post bariatric hypoglycemia and potentially congenital hyperinsulinism. The recent supply deals with Bachem and Polypeptide line up drug substance capacity ahead of LUCIDITY Phase III data, which keeps the focus firmly on that Q3 2026 readout as the key near term swing factor. The same agreements lift future fixed commitments starting in 2028, so if approval or uptake do not materialise, cash flexibility could tighten faster than expected.
The most relevant nearby event is management’s upcoming fireside chat at the Morgan Stanley Global Healthcare Conference on 15 September 2026. That session gives Amylyx Pharmaceuticals a forum to walk investors through how these avexitide manufacturing commitments fit with its 2027 launch preparations, ongoing NDA drafting and broader GLP 1 antagonist plans. It also offers a chance for questions on minimum purchase obligations, pricing mechanics and capital runway, all of which sit alongside clinical data as practical levers for the story in the next 12 to 24 months.
That said, tucked just behind this cleaner avexitide story sits ...
Read the full Amylyx Pharmaceuticals narrative to see the case behind these numbers.
Amylyx Pharmaceuticals’ current consensus storyline points to US$168.0 million in revenue and US$36.4 million in earnings by 2029. This implies moving from zero revenue today and turning a current earnings loss of US$150.1 million into positive earnings, a swing of about US$186.5 million.
Amylyx Pharmaceuticals' forecasts point to a $25.56 fair value compared with a $32.40 share price, a 21% downside to its current price that leaves little room for error.
Exploring Other Perspectives
One alternate storyline puts less weight on avexitide’s launch potential and more on margin pressure. Those analysts saw only US$78.0 million of revenue and US$17.1 million of earnings by 2029, and some even anticipated a US$259.9 million loss. That is a far more cautious view than consensus, and the fresh Amylyx Pharmaceuticals supply commitments may ultimately prompt both camps to reconsider their numbers.
To see how other investors are valuing Amylyx Pharmaceuticals, compare this view with 1 other fair value estimates for Amylyx Pharmaceuticals.
The Verdict Is Yours
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so consider your own assessment.
- A great starting point for your Amylyx Pharmaceuticals research is our analysis highlighting 2 key rewards and 4 important warning signs that could impact your investment decision.
- See our latest analysis for Amylyx Pharmaceuticals. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Amylyx Pharmaceuticals' overall financial health at a glance.
Looking For More Ideas Beyond Amylyx Pharmaceuticals?
If Amylyx Pharmaceuticals has sharpened your thinking but you want a wider watchlist, the Simply Wall St Screener gives you plenty of ways to pressure test your next move across different types of companies.
- For investors who want quality at a discount, check out 49 high quality undervalued stocks that match strong fundamentals with prices that may not fully reflect them yet.
- If capital preservation comes first for you, focus on steadier profiles by scanning through 80 resilient stocks with low risk scores that carry lower risk scores.
- For those hunting early stage potential, cast a wider net with 20 elite penny stocks with strong financials that pair smaller market caps with more speculative upside.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com